Bavelloni, A., Piazzi, M., Ramazzotti, G., Fiume, R., Blalock, W., & Faenza, I. (2017). PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma. Italian Journal of Anatomy and Embryology, 122(1), 21. https://doi.org/10.36253/ijae-1730